Industry Sessions
Corporate Industry Symposia
The basis of bone-building: Exploring the mechanisms by which bone-forming therapies impact bone strength
Sunday May 8th 2022 – Auditorium 103
14:45 – 14:50 EEST | Welcome and introduction | Ralph Müller (Switzerland) |
14:50 – 15:05 EEST | The anatomical significance of bone modeling and remodeling | Ralph Müller (Switzerland) |
15:05 – 15:20 EEST | The impact of bone-forming therapies on cortical and trabecular bone structure | Richard Abel (United Kingdom) |
15:20 – 15:35 EEST | Translating therapeutic effects into clinical outcomes | Roland Chapurlat (France) |
15:35 – 16:10 EEST | Q&A/panel discussion | All, led by Ralph Müller (Switzerland) |
16:10 – 16:15 EEST | Conclusion and closing remarks | Ralph Müller (Switzerland) |
This symposium is sponsored and organised by UCB and co-supported by Amgen.
Corporate Mini Symposia
Osteoporosis: the link between experimental findings and clinical observations
Saturday May 7th 2022 – Auditorium 103
13:30 – 13:40 EEST | Welcome and introduction | Heikki Kröger (Finland) |
13:40 – 14:15 EEST | New insights into denosumab mechanisms of action in relation to its long-term and off-treatment effects on bone | Serge Ferrari (Switzerland) |
14:15 – 14:30 EEST | Q&A session and meeting close | Serge Ferrari (Switzerland)
Heikki Kröger (Finland) Núria Guañabens (Spain) |
Exploring how people living with Rare Bone Diseases can contribute to the drug development process: Design for them or with them?
Supported by an independent educational grant from Ipsen
Sunday May 8th 2022 – Meeting room 207
19:00 – 19:10 EEST | Collaborative research with people living with Rare Bone Diseases and advocates – why, when, and how | Inês Alves (Portugal) |
19:10 – 19:25 EEST | Exploring how people living with Rare Bone Diseases can inform Early Research | Oliver Semler (Germany) |
19:25 – 19:40 EEST | Exploring how people living with Rare Bone Diseases can inform Clinical Research | Clemens Stockklausner (Germany) |
19:40 – 20:00 EEST | Panel discussion and Q&A | All, led by Inês Alves (Portugal) |